Phase II Study on NIVolumab in combination with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan)/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer patients with mutated RAS or BRAF genes.
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2538383
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: Evaluate the activity of Nivolumab in combination with FOLFOXIRI and bevacizumab.
Primary endpoints: To demonstrate that adding nivolumab to standard colorectal first line chemotherapy improves the Overall Response Rate as determinated by investigators using RECIST 1.1 criteria.
创建时间：
2019-03-15
